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1. Introduction  
Restless legs syndrome (RLS) is a common clinical entity consisting of an uncomfortable 
sensation in one’s legs and irresistible urge or desire to move them usually occurring in the 
evening. This syndrome has been sub optimally diagnosed in the past and remains overall 
misunderstood and under-recognized by many primary health care providers. However, 
RLS is increasingly recognized to cause significant disease burden and decreased quality of 
life (Kushida C et al., 2007). The initial modern clinical description was published by Ekbom 
in 1945 but was largely ignored until the late 1980s when there was a resurgence of interest 
in RLS (Walters AS & Hening W, 1987). Because of ongoing clinical confusion and the need 
for more clear epidemiologic assessment, a research group was organized in 1995 and the 
original IRLSSG criteria were developed (Walters AS, et al., 1995). In 2003, the International 
Restless Legs Syndrome Study Group (IRLSSG) issued revised guidelines to assist in clinical 
diagnosis and research of RLS (Allen RP et al., 2003). 
2. RLS description and diagnosis 
RLS is described by the RLS foundation as a neurological condition that is characterized by 
the irresistible urge to move the legs. Patients will describe an uncomfortable itching or 
“creepy-crawling” sensation on the legs in the evenings and report that it feels like “bugs 
crawling under the skin.”  The IRLSSG has listed 4 essential criteria to clinically diagnose 
RLS. Physical examination is usually normal. There is no single test used which will make 
the diagnosis although many patients suffer from iron deficiency with low ferritin levels. 
While overnight polysomnography (PSG) in a sleep laboratory is helpful to assess periodic 
limb movements of sleep (PLMS), a PSG is not necessary to make the clinical diagnosis of 
RLS. PLMS are defined as a repetitive or periodic bursts of leg (or arm) electromyographic 
(EMG) activity during sleep associated with discrete, stereotypical movements of the legs or 
arms. PLMS are felt to be a related but separate disease from RLS. Although most (80%) 
patients with RLS with have PLMS on PSG testing, approximately 12-20% of RLS patients 
will not have evidence for PLMS (Montplaisir J et al., 1997). Approximately 30% of patients 
with PLMS will have RLS symptoms. The revised 2003 IRLSSG essential criteria include 1) 
An urge to move the legs accompanied or caused by uncomfortable sensations in the legs, 2) 
The urge to move or unpleasant sensations beginning or worsening during periods or rest 
or inactivity such as lying or sitting, 3) The urge to move or unpleasant sensations are 
partially or totally relieved by movements such as walking or stretching, at least as long as 
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the activity continues, 4) The urge to move or unpleasant sensations are worse in the 
evening or night than during the day or only occur in the evening or night (Allen RP et al., 
2003). Despite these revised guidelines, there are still difficulties in excluding mimics such 
as leg cramps that can confound the diagnosis and the specificity of the 4 diagnostic criteria 
is 84% (Hening WA et al., 2009). It has been suggested that the validated self-completed 
Cambridge-Hopkins RLS questionnaire (CH-RLSq) is more useful with a sensitivity of 
87.2% and a specificity of 94.4%. (Allen RP et al., 2008). In addition to the diagnostic criteria, 
the IRLSSG developed a validated, patient-completed 10 item severity rating scale called the 
IRLS severity scale or IRLSSS (Walters AS et al., 2003). 
3. RLS prevalence 
RLS has been mainly studied in North America and Europe and appears to have a 
prevalence of 5 to 15% with up to a 2:1 female ratio (Berger K et al., 2004, Phillips B et al., 
2000). Prevalence is markedly higher in certain groups such as Icelandic women where RLS 
prevalence was found to be 24.4% (Benediktsdottir B et al., 2010). Of interest, the increased 
risk of RLS in women appears to be linked to parity with an increased risk of RLS directly 
proportional to the number of children (Berger K et al. 2004). In contrast, nulliparous 
women have the identical risk of RLS as men the same age. While, most of the epidemiology 
of RLS has been researched in Europe and North America, there are studies from other 
areas. Research from Asia appear to yield lower prevalence rates. (Chen NH et al., 2010). 
Overall, the prevalence of RLS appears to be higher in North American/European 
populations, especially in women. 
4. RLS pathogenesis 
The scientific basis of RLS remains unclear but appears to be related in part to the 
dopaminergic pathways and iron metabolism in the substantia nigra. In 2003, Connor et. 
al. published an autopsy-based study suggesting that the cause of RLS was related to a 
defect in the regulation of transferrin receptors in the brain (Connor JR, et al., 2003). In 
addition, MRI, PET, and SPECT imaging studies have likewise shown alterations in the 
dopaminergic receptors of the brain (Michaud M et al., 2002). Recently, further evidence 
has accumulated to support that there is a primary iron insufficiency leading to an overly 
activated dopaminergic system (Connor JR et al., 2009, Quiroz C et al., 2010). Low iron 
levels can increase extracellular dopamine and decrease D2 receptors (Earley CJ et al., 
2011). Thus, overall the pathophysiologic basis of RLS is not fully understood but there is 
increasing evidence of iron deficiency related dopaminergic abnormalities. In addition to 
dopamine and iron physiology, there are clear familial clusterings and genetic linkages. In 
2007, researchers in Iceland reported on the first genetic variant associated with a 
susceptibility to periodic limb movements of sleep (Stefansson H et al., 2007). A total of 4 
main genetic variants have since been discovered which account for approximately 80% of 
primary RLS. 
5. Primary RLS 
RLS is divided into two main categories which are primary (idiopathic) RLS and secondary 
RLS. Patients with primary RLS tend to have onset at an earlier age, often under age 45. In 
addition, there is a significantly higher family history of RLS (Allen RP & Earley CJ, 2000). 
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6. Clinical associations with RLS or secondary RLS 
6.1 RLS and multiple sclerosis 
After an initial 2002 meeting presentation where data from 100 multiple sclerosis (MS) 
patients with a prevalence of RLS of 32%was described, Auger et al reported a prevalence of 
37.5% in their 200 French-Canadian MS patients meeting the 2003 IRRLSG criteria. 
Interestingly, in their patient population, more women than men met RLS criteria and 30% 
of patients reported that RLS symptoms started or worsened during pregnancy. A positive 
family history for RLS was reported by 36% of these French-Canadian patients meeting RLS 
criteria. They speculated whether MS plaque formation and involvement in the basal 
ganglia may be pathogenic for RLS in these patients. This concept may be supported by the 
therapeutic effect of dopaminergic therapeutic agents. The concept of potential common 
susceptibility genes for both MS and RLS is raised by the authors (Auger C et al, 2005). The 
following year, Kilfoyle et al reported a myelin protein zero (MPZ) mutation which was 
associated in the individuals studied with various neurological manifestations including 
RLS and MS (Kifoyle DH, et al, 2006). 
In 2007, Manconi et al examined prevalence of RLS in an Italian population of MS patients. 
In this population of 156 patients, 100 were female and a prevalence of 32.7% was found 
who met the 2003 IRRLSG diagnostic criteria. However, in contrast to the French-Canadian 
population, a positive family history for RLS was only reported by 5% of the (total) 
population. In the majority of these patients (> 90%), RLS symptoms followed or were 
simultaneous in onset with MS clinical features onset. The authors speculate that the co-
existence of MS and RLS may be the result of a particular lesional pattern (Manconi et al, 
2007). In a subsequent study of 82 MS patients of whom 30 patients had co-existing RLS, 
brain and cervical spinal cord MRIs were done. The MS and RLS patients were observed to 
have a greater degree of cervical cord involvement than those MS patients without RLS. The 
authors state that cervical cord damage represents a significant risk factor for RLS in MS 
patients (Manconi et al, 2008).  
The Italian REMS Study Group, published the ‘REstless legs syndrome in Multiple Sclerosis’ 
or REMS study in 2008 in the journal SLEEP. This group reported a prospective, multicenter 
case-control epidemiologic survey which involved 20 sleep centers certified by the Italian 
Association of Sleep Medicine and included 861 MS patients and 649 control patients. They 
reported a 19% prevalence of RLS, using the IRRLSG criteria, in the MS patients compared 
to a 4.2% in the control population. This provided a relative risk for RLS in the MS patients 
of 5.4. Risk factors associated with RLS in the MS patients were identified as older age, 
longer duration of MS, the primary progressive form of MS, higher global, pyramidal, and 
sensory disability and the presence of leg jerks before sleep onset. Additionally, RLS 
symptom severity was reported to be worse in the MS patient group compared to symptoms 
of control group patients with RLS. The authors comment that their results strengthen the 
hypothesis that MS inflammatory lesions may induce a secondary form of RLS (The Italian 
REMS Study Group, 2008). 
In a study of French patients with MS by Douay et al, the authors report a prospective 
evaluation of 242 MS patients and found 18% met the international RLS criteria, consistent 
with the REMS study report. In this French population, the authors reported RLS symptoms 
to be more frequent in patients with the relapsing-remitting form of MS (Douay et al. 2009). 
A Brazilian study of 44 MS patients reported by Moreira et al, found 27% of their patients 
met the RLS criteria. The authors did not observe any association of specific patient 
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characteristics associated with the presence of RLS compared to those MS patients not 
meeting RLS criteria, in this small prevalence study (Moreira et al, 2008). 
Deriu et al published a case-control study of Italian MS patients. The authors enrolled 202 
MS patients and 212 age and gender matched healthy controls. Interestingly, 45% of the MS 
patients met the IRRLSG diagnostic criteria for RLS, however, after neurologic review and 
examination of the each patient who responded positively to the questionnaire instrument, 
only 14.6% of the MS patients were felt to truly have a diagnosis of RLS. In the control 
group, 16.03% were positive responders to the questionnaire criteria, but only 2.8% had a 
final diagnosis of RLS following neurologic review and examination. The authors comment 
on the high false positive number of questionnaire responders (Deriu et al, 2009). 
In summary, there is evidence of an increased prevalence of RLS in the MS population. 
Several interesting possibilities have been suggested to explain this association. The weight 
of evidence seems to support the concept of a secondary RLS likely arising from strategic 
geographic involvement of demyelinating lesions. 
6.2 RLS and other neurologic disorders 
Peripheral neuropathy has also been associated with RLS. A recent case-control study (Hattan 
E et al 2009) in a Quebec population examined 245 patients with a diagnosis of peripheral 
neuropathy and 245 age and gender matched controls. The authors considered a positive 
response to three of the four essential criteria to be ‘screen-positive’. All ‘screen-positive’ 
patients were subsequently evaluated by a blinded movement disorders specialist. Of the 245 
peripheral neuropathy patients, 26.5% were ‘screen-positive’, compared to 10.2% of controls. 
Confirmation by neurologist, however, revealed only 46% of the ‘screen-positive’ peripheral 
neuropathy patients were felt to truly have a diagnosis of RLS compared to 80% of the ‘screen-
positive’ control patients. After this diagnostic confirmation, the overall prevalence of RLS did 
not differ between the peripheral neuropathy patients and the control group. 
The prevalence of RLS was evaluated in a cohort of 99 Italian patients with acquired diabetic 
peripheral neuropathy (Gemignani et al, 2007). Using IRRLSG diagnostic criteria, RLS was 
found to be present in a third of the patients in this study population (33/99). The authors 
reported that of the various forms of diabetic neuropathy represented within this 
population, small fiber sensory neuropathy was more common than other forms. A 
prominent symptom associated with RLS was ‘burning feet’. The authors suggest that RLS 
may be triggered peripherally by abnormal sensory inputs from small fibers.  
A case series of 12 patients with essential mixed cryoglobulinemia and associated peripheral 
neuropathy reported a frequency of RLS, using pre-2003 diagnostic measures, of one third 
(4/12) (Gemignani et al, 1997).  
A recent report (Bachmann CG et al 2010) suggest response to specific stimuli may be able to 
distinguish between primary RLS and RLS secondary to small fiber neuropathy. In this 
study of 21 primary RLS patients and 13 patients with secondary RLS related to small fiber 
neuropathy, the authors describe thermal hypoesthesia to cold and warm in those with 
secondary RLS compared to both the primary RLS study patients and controls. They also 
suggest support for the RLS pathogenesis concept of central disinhibition of nociceptive 
pathways which might be induced by conditioning afferent input from damaged small fiber 
neurons in secondary RLS. 
Restless legs syndrome has been reported as increased in prevalence in German hereditary 
spastic paresis patients (Sperfeld AD, et al, 2007) and in Argentinian patients with Fabry’s 
disease (Dominguez RO, et al, 2007). RLS has also been reported to be present in 18.1% of 
www.intechopen.com
 
Risk Factors and Treatment of Restless Legs Syndrome in Adults 
 
163 
227 Charcot-Marie Tooth disease patients compared to 234 controls with a 5.6% prevalence. 
RLS severity was correlated with worse sleep quality and reduced health-related quality of 
life measures. Variation in prevalence was not observed between subtypes of Charcot-Marie 
Tooth disease, but women were more severely affected by RLS than male patients (Boentert 
M, et al 2010). A series of 28 patients with Friedreich’s Ataxia were surveyed for prevalence 
of RLS with 32% meeting diagnostic criteria (Synofzik M et al, 2011). In a population of 28 
chronic inflammatory demyelinating polyneuropathy (CIDP), a prevalence of 39.3% for RLS 
was found, compared to 7.1% prevalence in age and gender matched control patients. 
Isolated case reports of RLS symptomatology following development of 
hyperparathyroidism (Agarwal P et al, 2008), administration of interferon therapy 
(LaRochelle JS, et al, 2004), development of multifocal motor neuropathy (Lo Coco D, et al, 
2009), and Guillain-Barré syndrome have been reported (Marin LF, et al, 2010). Additionally, 
a case report has been published reporting a patient who experienced remission of severe 
RLS following excision of multiple foot neuromata (Lettau LA, et al 2010). 
The question has also been raised as to whether RLS in seen in a higher prevalence in 
patients with Parkinson’s Disease. This has been addressed in an Italian population of 118 
Parkinson’s Disease outpatients using a case-control study design. The authors report a 
failure to demonstrate increased prevalence of RLS in the Parkinson’s patients in 
comparison to age and gender matched control patients. They further acknowledge the RLS 
prevalence assessment may be impeded by the concurrent treatment of Parkinson’s Disease 
with dopaminomimetic drugs, which may also be expected to impact on RLS 
symptomatology (Calzetti et al, 2009). Another study from the Netherlands in 269 non-
demented Parkinson’s Disease patients, found RLS to be present in 11% of patients. RLS 
severity was noted to correlate positively with Parkinson’s Disease severity. RLS was also 
significantly more common in male patients than female. The authors note the similar 
prevalence of RLS in their study population to the general population and submit that this 
could potentially relate to concurrent dopaminergic therapy. They also suggest that in view 
of the relationship of severity of RLS to severity of Parkinson’s Disease related primarily 
non-dopaminergic symptoms, that non-dopaminergic systems may play a role in any 
potential relationship between RLS and Parkinson’s Disease (Verbaan D, et al, 2010). 
In a reverse style of assessment, 23,119 participants in the Health Professional Follow-up study 
who were free of diabetes and arthritis were surveyed. The IRRLSG diagnostic criteria were 
applied and concurrent diagnoses of Parkinson’s Disease were investigated. The adjusted 
odds ratios for Parkinson’s Disease in men with RLS symptoms with frequency from 5-14 
times per month was 1.1, and in those with a frequency of RLS of 15 or more times per month 
the odds ratio was higher at 3.09. The authors concluded that men with RLS symptomatology 
were more likely to have concurrent Parkinson’s Disease (Gao X, et al, 2010).  
6.3 RLS and pregnancy 
Lower extremity symptoms consistent with RLS have been reported in pregnancy. In a 
study of 642 pregnant Italian women, data was collected around the time of delivery and at 
follow-up evaluation up to six month post-delivery. Patients were screened with the 
IRRLSG diagnostic criteria. The authors reported that 26% of women acknowledged 
symptoms of RLS during their pregnancy. It was most strongly related to the last trimester 
of the pregnancy and tended to disappear around the time of delivery. The authors 
concluded that pregnancy was associated with transient RLS. They did also observe that 
women with RLS symptoms had lower hemoglobin levels and MCV compared to healthy 
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subjects. (Manconi M et al, 2004). An American study of 189 nulliparous women who were 
enrolled between six and 20 weeks of gestation and were followed up in the third trimester, 
reported an increase in patients meeting RLS criteria from 17.5% at enrollment up to 31.2% 
in the third trimester (Facco FL, et al, 2010). 
In a questionnaire study of female members of the French Association of Patients with RLS, 
Ghorayeb et al applied both the International RLS Severity Scale (IRLSSS) and a 
questionnaire addressing reproductive behaviour and RLS history. Interestingly, women 
who had had a pregnancy showed a higher mean IRLSSS score than women who had never 
had a child. Worsening of symptoms during pregnancy were reported by 23% of patients, 
29% of non-menopausal women reported increased severity of RLS symptoms during 
menses, and 69% of women reported worsening of symptoms following menopause 
(Ghorayeb I, et al, 2008). An Australian case-control study of pregnant women 
demonstrated a RLS prevalence of 22.5% of 211 women. A positive family history of RLS 
and of ‘growing pains’, as well as a personal childhood history of ‘growing pains’ were 
associated with meeting RLS criteria in this study population (Balendran et al 2011). 
In a Turkish study of 146 pregnant women, 38 were diagnosed with RLS. The authors report 
lower hemoglobin levels to be a risk factor for RLS in pregnancy (Tunc et al 2007). In a study 
of pregnant women in Pakistan, 81 of 271 women met diagnostic criteria for RLS. The 
authors reported anemia and a positive family history of RLS to be predictive for 
development of de novo RLS, whereas, a positive family history for RLS and multiparity 
were predictors for pre-existing RLS with odds ratios of 12.39 and 6.84 respectively 
(Sikandar R, et al,  2009). A previous pregnancy was also identified by Pantaleo NP et al as a 
significant risk factor for RLS in a re-analysis of data from a prior RLS study. They observed 
that in family members of RLS probands, the prevalence of RLS was significantly higher for 
parous women (49.5%) than for nulliparous women (33.7%) or for men (30%). These 
differences were not observed in control proband family members. The authors suggest that 
in patients with a positive family history of RLS, pregnancy has a major influence on the risk 
of developing RLS (Pantaleo NP, et al, 2010).  
Examining hormonal influences on RLS, Dzaja et al, studied 10 pregnant German women 
with RLS and nine healthy pregnant controls.  Blood hormone levels of estradiol were 
higher in patients with RLS than in control patients. The authors suggest estrogens may 
contribute via a pathophysiological mechanism to triggering of RLS symptoms during 
pregnancy (Dzaja A, et al, 2009). 
Neau et al, in a cross-sectional questionnaire study of 1.022 pregnant French women from a 
single town, screened for RLS using IRRLSG criteria. They found 24% of these women to be 
affected by RLS during their pregnancy. The symptoms of RLS were strongly related to the 
third trimester of the pregnancy. In a follow-up study of a smaller number of patients, the 
authors report resolution of RLS symptoms within a short time interval following delivery 
in the majority of women (Neau JP et al, 2010a, Neau JP et al, 2010b). A follow-up study of 
RLS in pregnant Italian women performed after a mean lapse of 6.5 years, reported on 74 
women with pregnancy associated RLS and 133 women who did not have RLS symptoms 
during their pregnancy. During the time between the original study and this follow-up 
investigation, the prevalence of RLS had increased to 56% person/year in women who had 
experienced RLS symptoms transiently during their pregnancy and 12.6% person/year in 
subjects who had not been troubled with RLS symptoms during pregnancy. The authors 
conclude the transient pregnancy RLS form to be a significant risk factor for development of 
a future chronic form of RLS (Cesnick et al, 2010). 
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6.4 RLS and renal disease 
Renal disease has been associated with RLS symptomatology.  A recent hospital based study 
of 301 patients, revealed a prevalence for meeting RLS criteria of 18.3%. Multivariate 
analysis identified iron deficiency and chronic renal disease to be independent predictors for 
RLS in this population (Quinn C et al, 2011). In a Japanese study of 490 uremic patients on 
hemodialysis (HD), 12.2% were found to meet criteria for RLS. The authors found a 
relationship between RLS, anxiety, anemia and high serum phosphorus level. They failed to 
find evidence of previously identified risk factors including relationship to gender, longer 
duration of HD therapy, frequency of HD sessions, and smoking (Takaki J et al, 2003).  The 
significance of an elevated serum phosphorus in RLS is unclear. 
A lower frequency of RLS was observed in an Indian study of 121 HD patients and 99 
controls, where only 6.6% of HD patients and 0% of controls met RLS criteria. Nerve 
conduction studies conducted on RLS patients found the majority to have evidence of 
sensori-motor neuropathy (Bhowmik D, et al, 2003). Another prevalence study in Brazil in 
176 HD patients observed a prevalence of RLS of 14.8% (Goffredo et al, 2003). A similar 
prevalence was established in 894 dialysis patients participating in the CHOICES (Choices 
for Healthy Outcomes In Caring for End Stage renal disease) study, where a prevalence of 
15% for ‘severe’ RLS was observed. Age and diabetes were positive predictors for RLS in 
this population. The authors also report an increase in the adjusted mortality hazard ratio of 
1.39 in patients with severe RLS. Reduced quality of life measures in these patients was also 
observed (Unruh ML, et al, 2004). In a small study from the Netherlands, 48 patients with 
renal disease and RLS were studied by polysomnogram (PSG) and questionnaire. A 
prevalence of 58.3% for meeting RLS criteria was observed. In addition the authors report 
nearly all RLS patients had evidence of severe periodic limb movement disorder on PSG 
(Riisman RM, et al, 2004).  Examining a population who were not yet dialysis dependent, 
Merlino et al enrolled 138 chronic renal failure patients and 151 controls. RLS criteria were 
met by 10.9% of the chronic renal failure group and 3.3% of the control population. An 
association with iron deficiency and female gender was observed (Merlino et al, 2005). 
6.5 RLS and rheumatic diseases 
In the rheumatoid arthritis (RA) patient population, increased prevalence of RLS has been 
reported by several investigators. Reynolds et al studied hospitalized RA patients 
employing a ‘control’ group of osteoarthritis (OA) patients, and found a 30% prevalence of 
RLS in RA compared to 3% in OA (Reynolds G et al, 1986). A subsequent study again 
comparing RA and OA found comparable prevalence rates for RLS of 25% in RA and 4% in 
OA (Salih AM, et al, 2004). Auger et al in their study of MS patients employed a RA patient 
group for contrast, finding a prevalence rate for RLS of 31% in their RA group (Auger C, et 
al, 2005). A more recent study employing the 2003 IRRLSG criteria for RLS found a 
prevalence of RLS of 27.7% in RA and a prevalence of 24.4% in OA patients (Taylor-Gjevre, 
et al, 2009). Increased frequency of RLS has also been reported in other rheumatic disease 
populations, including Sjogren’s Syndrome, scleroderma and fibromyalgia patients (Taylor-
Gjevre, et al, 2011). A recent study of RLS in Systemic Lupus Erythematosus patients has 
also suggested an increased prevalence in that population (Hassan N, et al, 2011). 
6.6 RLS and Iron deficiency 
An increased prevalence of anemia or iron deficiency has been observed in many RLS patient 
populations. Treatment with iron supplementation has been efficacious in many cases of RLS 
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in patients with low serum ferritin levels. This is discussed in greater depth in the treatment 
section of this chapter. Consistent with these observations, there has been an increased 
prevalence of RLS in patients with celiac disease, a disorder with associated abnormal iron 
absorption (Moccia M, et al, 2010) and as mentioned previously in this chapter, many instances 
of secondary RLS appear to be also associated with anemia or low iron status. 
There have been several studies assessing prevalence of RLS in regular blood donors. A 
large Swedish study of 946 consecutive blood donors, aged 18-64, who were evaluated for 
RLS, found a gender difference in prevalence. In male blood donors 14.7% met RLS criteria, 
in female donors the frequency increased to 24.7%. Further, in patients with laboratory 
evidence consistent with iron-deficiency, the frequency of RLS increased to 37.5%. The 
authors conclude RLS to be common amongst female blood donors (Ulfberg J, et al, 2004). 
Conversely, in an American study of 144 blood donors, only a 4% prevalence of definite RLS 
was appreciated. The authors comment that their relatively small sample size may influence 
their results (Arunthari V, et al, 2010).  
From a pathologic viewpoint, decreased iron content has been observed in the substantia 
nigra which is felt to contribute to the pathophysiology of RLS (Synder AM, et al, 2009). In a 
recent study, Connor et al examined expression of iron management proteins in proximity 
to the blood-brain interface in brains from eleven RLS patients and in 14 control brains. The 
authors report a significant decrease in heavy chain ferritin, transferrin and it’s receptor in 
the microvessels in RLS patients compared to controls. Additionally, activity of an iron 
regulatory protein was observed to be diminished in the RLS patients compared to controls. 
These relative differences between brains from RLS patients and control patients suggest 
fundamental differences in brain iron acquisition in RLS patients (Connor JR, et al, 2011) 
7. Treatment options for RLS 
Historically, there were a variety of treatments for RLS ranging from bloodletting to opiates. 
Indeed, Sir Thomas Willis over 325 years ago described the first probable case of RLS and 
used opium to alleviate the symptoms. When RLS was “rediscovered” by researchers in the 
1980s, once again opioid narcotics were the treatment of choice (Hening WA, et al. 1986). In 
that study, five patients with RLS were given opioid drugs which relieved their awake RLS 
symptoms as well as PLMs and sleep disturbance. When counteracted with intravenous 
naloxone, the RLS symptoms and findings returned leading the authors to speculate on the 
endogenous opiate system playing a role in RLS pathogenesis. However, with increasing 
research in the last two decades, it has become clear that the underlying pathology of RLS is 
largely due to alternations in dopaminergic pathways. This has lead to the use of both non-
specific and specific dopamine receptor agents. 
7.1 Pharmacological treatments for RLS 
7.1.1 Iron replacement therapy 
While Ekbom did recognize the possible role of iron therapy in RLS, it was not until 1994 
when O’Keeffe in Dublin did the first clinical trial of iron replacement therapy. In that study 
of 18 elderly patients with 18 matched controls, iron status and RLS response to iron therapy 
was observed. The researchers found that serum ferritin levels were reduced in RLS subjects 
compared to the control group and that levels were inversely correlated to the severity of 
RLS symptomatology. In the 15 RLS patients treated with iron replacement therapy for 2 
months, there was a significant improvement in RLS symptoms (O’Keeffe ST, 1994). In a 
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recent double-blinded, placebo-controlled study, Wang and colleagues showed the benefit 
of iron replacement in RLS patients with low serum ferritin. In this study, 373 patients were 
screened and 157 (42%) met the 2003 IRLSSG criteria for RLS. Of these, there were only 18 
patients who consented to participate and met the inclusion criteria (which included having 
a low-normal serum ferritin between 15-75 ng/ml). Eleven patients were randomized to iron 
replacement (ferrous sulfate 325mg po bid) and 7 to placebo for 12 weeks and IRLS scores 
were obtained at the start and end of the study. The researchers found a clinically significant 
(p = 0.01) improvement in IRLS scores in the iron therapy group and a non-significant (p = 
0.07) trend towards improvement in quality of life (Wang J, 2009). 
7.1.2 Dopamine precursors 
Dopamine is a catecholamine which acts as a neurotransmitter but cannot cross the blood-
brain barrier. Levodopa (L-DOPA) is a precursor to dopamine (as well as norepinephrine 
and epinephrine) and can cross the blood-brain barrier. Once in the brain, L-DOPA is 
converted by DOPA decarboxylase to dopamine which can act on the dopamine receptors to 
treat RLS. However, because peripheral L-DOPA is also converted to dopamine leading to 
adverse effects, L-DOPA is usually given with a peripheral DOPA decarboxylase inhibitor 
(usually carbidopa). There is a large body of evidence supporting the effectiveness of L-
DOPA in RLS. One of earliest randomized trials was done in the USA and published in 
1993. This study was a randomized, double-blind, placebo-controlled, cross-over design trial 
evaluating carbidopa/levodopa with proproxyphene and placebo. The primary outcome 
was PSG measurements and sleep latency tests. The researchers found that 
carbidopa/levodopa normalized the PLMs and improved sleep, especially in the first 3 
hours of sleep (Kaplan PW et al., 1993). However, it soon became apparent that 
carbidopa/levodopa had a serious drawback in regards to augmentation or rebound of RLS 
symptoms the following morning and/or early afternoon. In a report from 1996, Allen and 
colleagues prospectively evaluated 46 consecutive patients being treated with 
carbidopa/levodopa. They found that 82% of RLS patients and 31% of PLMS patients 
experienced augmentation problems and this was severe enough to lead to medication 
changes in 50% of the RLS patients (Allen RP, Earley CJ, 1996). Because of augmentation 
issues, other researchers have evaluated using sustained-release L-DOPA preparations. 
Trenkwalder and colleagues did an open-label extension trial of an earlier double-blinded, 
cross-over study evaluating standard and sustained-release L-DOPA. In this 1 year trial they 
found that 60% of patients discontinued therapy due to aggravating daytime symptoms 
(Trenkwalder C et al., 2003). In a 2006 review, Paulus & Trenkwalder examined the world 
literature and concluded that augmentation is a result of severely increased dopamine 
concentration in the CNS and that overstimulation of the D1 receptors compared to the D2 
receptors in the spinal cord may cause discomfort and PLMS. Also, iron deficiency may be a 
significant predisposing factor for the development of augmentation. The researchers 
concluded that therapy with L-DOPA or dopamine agonist should endeavour to be low-
dose and that iron replacement and/or opiates are the therapies of choice to use with 
augmentation (Paulus W & Trenkwalder C, 2006). In summary, L-DOPA is a widely 
available and inexpensive therapy for RLS which has been shown in numerous studies to be 
beneficial in improving objective PSG findings as well as subjective measures of sleep and 
RLS symptoms. Unfortunately, there are problems particularly linked to L-DOPA with next 
morning augmentation of RLS symptoms. This does impair the usefulness of L-DOPA 
especially when there are newer effective dopamine agonists with a better side effect profile. 
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7.1.3 Ergot-derived dopamine agonists 
Ergotamine is related to ergot alkaloids and is structurally similar to several neurotransmitters 
including dopamine. Ergotamine derivatives include bromocriptine, pergolide, and 
cabergoline. It most be noted that all ergot derivatives have been associated with cardiac valve 
disease. In a recent Italian study, researchers found that patients taking pergolide or 
cabergoline had a relative risk of 4.2 to 6.3 for valve regurgitation compared to patients using 
non-ergot dopamine agonists and controls (Zanettini R, 2007). Thus it is recommended to 
conduct close cardiac monitoring in patients on ergot-derived dopamine agonists.  
Bromocriptine is an ergot-derivative dopamine agonist that preferentially acts on the D2 
dopamine receptor. It has traditionally been used in the treatment of pituitary tumors and 
Parkinson Disease but has been tried for RLS with some efficacy. In a small, double-blinded, 
randomized crossover study, researchers found that 83% of patients had partial subjective 
improvement in RLS symptoms but no significant change in PLMD by PSG (Walters AS, 
1988). A more recent study from Europe compared bromocriptine to pramipexole (a 
preferential D3 receptor agonist) showing that while both helped to improve RLS 
symptoms, pramipexole was superior. In addition, pramipexole improved PSG parameters 
including PLM frequency (Manconi M, 2011). Thus, bromocriptine is not commonly used as 
a therapy for RLS at this time. 
Pergolide is a semi-synthetic ergot-derivative that acts as a dopamine agonist at both the D2 
and D1 receptors. In a major study, Trenkwalder and colleagues found pergolide 
significantly improved RLS symptom severity and PLMD (Trenkwalder et al. 2004). The 
researchers conducted a double-blinded, placebo-controlled, randomized study of pergolide 
therapy; the Pergolide European Australian RLS  (PEARLS) study. In this study, 100 
patients with primary (idiopathic) RLS were randomized to either pergolide or placebo for 6 
weeks. In addition, there was a 12 month follow-up phase with open-label pergolide for 
placebo non-responders. PLMS were assessed by PSG and RLS symptoms by the IRLS 
severity scale (IRLSSS) questionnaire. They found that pergolide significantly improved 
IRLSSS results at 6 weeks. In addition, the pergolide treated patients had substantial 
improvements in the 6 week and 12 month PLM index. The authors concluded that 
pergolide significantly improves PLM findings as well as subjective RLS sleep disturbance. 
Cabergoline is a newer, semi-synthetic, long-acting, ergot-derivative dopamine agonist that 
particularly acts on the D2 receptors but also has some affinity for the D1 and D3 receptors. 
One of the earliest studies examining cabergoline in RLS was from Germany in 2000. In that 
study, researchers conducted a 12 week open label trial assessing efficacy with baseline and 
12 week PSG and RLS subjective questionnaires. The research team found improvements in 
PLMs and subjective relief of symptoms and concluded that cabergoline was effective and 
well-tolerated (Stiasny K et al., 2000). A more recent randomized, double-blinded, placebo-
controlled, multicenter PSG study examined the efficacy of cabergoline in RLS (the CATOR 
study). In this study, 40 patients with moderate to severe RLS were randomized to either 
cabergoline or placebo for 5 weeks. Baseline and end of study PSGs were obtained as well as 
IRLSSS and quality of life questionnaires. The researchers found the cabergoline group had 
significant improvements in PSG parameters, IRLSSS severity scores, and the RLS quality of 
life scores. They concluded that cabergoline is an efficacious and well-tolerated therapy for 
RLS symptoms and associated sleep abnormalities (Oertel WH et al., 2006). Unfortunately, 
like pergolide, cabergoline has been implicated in cardiac valvular heart disease and 
patients treated with this agent need close cardiac monitoring. 
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7.1.4 Nonergot-derived dopamine agonists 
There are three newer fully-synthetic dopamine agonists that are not derived from ergot. 
The three drugs include ropinirole, pramipexole, and rotigotine. As of July 2011, rotigotine 
is not approved by the FDA for use for RLS in the USA. These nonergot agents are not 
associated with valvular heart disease but have been associated with impulse control 
disorders including pathological gambling, compulsive overeating, hypersexuality, and 
pyschosis. There is increasing recognition that patients treated with these agents should be 
monitored for impulse control disorders. 
Ropinirole acts as a dopamine agonist primarily on the D3 as well as D2 & D4 receptors. It 
was originally studied in the early 1990s for Parkinson’s Disease and later found to be 
beneficial for RLS. Ondo studied 16 RLS patients in an open-label trial of ropinirole. Three 
patients discontinued ropinirole use. Of the remaining 13 patients, the average duration of 
use was 3.9 months and there was a 58.7% improvement in symptoms (Ondo W, 1999). 
Further studies reinforced the safety and efficacy of ropinirole in RLS. The TREAT RLS 1 
study (Therapy with ropinirole; efficacy and tolerability in RLS 1) was a randomized, 
double-blinded, placebo-controlled trial of 12 weeks duration. 146 subjects were 
randomized to the ropinirole group and 138 to the placebo group. The key endpoint was the 
IRLS severity score which showed significant improvement in the ropinirole group over the 
placebo group at week 12 (p=0.0036). The researchers concluded that ropinirole improves 
RLS compared with placebo and was generally well-tolerated (Trenkwalder C et al. 2004). 
More recent similar studies from the USA and Canada confirm the efficacy and safety of 
ropinirole, including long-term duration in the Canadian study. In the USA study, Bogan 
and colleagues studied 331 subjects in a multicenter, double-blinded, placebo-controlled, 
flexible dose trial of 12 weeks duration. The primary endpoint was the IRLS score at week 12 
which showed a significant improvement in the ropinirole group (p<0.001). In addition, the 
treatment group showed improvements in subjective measures of sleep disturbance and 
quantity and quality of life scores also improve. The authors concluded that ropinirole 
improves RLS symptoms and was generally well-tolerated over a 12 week study period 
(Bogan RK et al. 2006). In the Canadian study, researchers studied the long-term efficacy (36 
weeks) of ropinirole and also evaluated for the potential of symptom relapse after drug 
discontinuation. They identified 202 patients and found significantly fewer subjects relapsed 
in the ropinirole arm compared to placebo (32.6% versus 57.8%, p=0.0156). In addition, the 
time to relapse symptoms was longer in the ropinirole group and less patients withdrew 
from lack of efficacy in that group. The authors concluded that ropinirole was highly 
efficacious and well-tolerated over a 36 week period (Montplaisir J et al. 2006). In 2008, Allen 
and colleagues reviewed RLS age-of-onset and the response to treatment. They observed no 
relationship between the RLS symptoms age-of-onset and baseline IRLS score, and between 
dose administered at week 12 and age-of-onset. The authors concluded that ropinirole 
provides effective RLS symptom relief that is not affected by age of symptom onset (Allen 
RP, Ritchie SY, 2008). In 2009, a large meta-analysis was conducted to evaluate the effect of 
ropinirole versus placebo on sleep outcomes as measured by the Medical Outcomes Study 
(MOS) sleep scale. The validated MOS sleep scale is a 12 question scale which evaluates 
sleep disturbance, sleep adequacy, snoring, somnolence, quantity of sleep, and other 
measures. In this review, the authors found that ropinirole improved sleep quality and 
decreased daytime somnolence in patients with primary RLS (Hansen RA, et al., 2009). 
Finally, researchers assessed the efficacy of ropinirole on depressive symptoms and RLS. In 
a multicenter, randomized, double-blinded, placebo-controlled trial, 231 patients with 
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moderate to severe primary RLS and at least mild depression were studied. Ropinirole 
versus placebo was given for 12 weeks with measurements obtained at baseline and 12 
weeks for the Montgomery-Asberg Depression Rating Scale, the Hamilton Scale for 
Depression and Beck Depression Inventory-II score, and the Medical Outcomes Study sleep 
scale. There were significant improvements in the Montgomery and Hamilton scores as well 
as 3 of the 4 domains of the MOS sleep scale. The authors concluded that in patients with 
RLS and mild to moderate depression, appropriate therapy for RLS should first be tried and 
antidepressant medication may be needed later if the depression symptoms still persist 
(Benes H et al., 2011). In summary, ropinirole is a newer nonergot-derived dopamine 
agonist with a particular affinity for the D3 dopamine receptors. It has been shown to be 
beneficial in RLS symptom improvement both short and long-term with improvement in 
daytime somnolence and quality of life indicators. 
Pramipexole is a nonergot-derived dopamine agonist that acts on the D3 as well as D2 and 
D4 receptors. One of the earliest RLS studies was conducted by Lin at the Mayo Clinic in 
1998. In that research, 16 patients were studied who had failed other dopaminergic therapies 
for symptomatic RLS. An open-label trial showed that after 2 to 3 months usage, there was 
clinically significant improvements in nocturnal leg restlessness and involuntary leg 
movements. The authors proposed that pramipexole was an effective therapy for the 
treatment of RLS (Lin SC et al., 1998). Following that encouraging initial report, a small 
randomized trial was conducted in Quebec. Researchers studied 10 RLS subjects with PSG 
and RLS symptom questionnaire using a double-blinded crossover study. They found a 
significant reduction in PLMs and RLS symptoms of bedtime/nocturnal leg discomfort 
(Montplaisir J et al., 1999). A larger randomized trial from Finland evaluated the efficacy 
and safety of pramipexole in 2006. In this study (the PRELUDE study), 109 patients with 
moderate to severe RLS (based on the IRSS severity score) were randomized in a 3 week, 
double-blinded, placebo-controlled, dose-finding study. PSG measures and IRLS severity 
scores were assessed. At all doses, the PLM index was reduced and IRLS severity scores 
reduced. The authors concluded that pramipexole was an effective and safe therapy for 
treatment of both the objective (PSG measures) and subjective (IRLS severity) aspects of RLS 
(Partinen M et al., 2006) In a long-term 52 week open-label study, Japanese researchers 
found that pramipexole was both effective and safe (with no RLS augmentation), especially 
in patients with an IRLS score less than 20 (Inoue Y, et al., 2010). In a more recent, 
multicenter trial, pramipexole was evaluated for efficacy and augmentation problems over a 
6 month period. This was a 6 month, randomized, double-blinded, placebo-controlled trial in 
which 321 patients were recruited. Primary endpoint for efficacy was the change in the IRLS 
severity score. In addition, patients maintained a symptom diary and cases that met pre-
defined criteria for suspected augmentation were reviewed by a blinded panel. The study 
showed that pramipexole was significantly more effective than placebo in improvements of 
IRLS severity (p=0.0077). Over 6 months, the incidence of confirmed augmentation was 9.2% 
in the pramipexole group versus 6.0% in placebo and the rate increased with treatment in the 
intervention group but not placebo. Overall, the authors felt that pramipexole was effective 
and safe but did suggest it should be studied over a longer duration for further assess 
augmentation issues (Hogl B, et al., 2011). More recent trials evaluating pramipexole has 
focused on comparison with other dopaminergic agonist. In a recent study by Manconi, 
pramipexole (mainly a D3 receptor agonist) was compared with bromocriptine (largely a D2 
receptor agent) and researchers found that pramipexole was more effective than 
bromocriptine in reduction of PLMs and that while both drugs reduced RLS symptoms, the 
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pramipexole group had greater symptom improvements (Manconi M et al., Neurology 2011). 
The same Italian group also did a recent comparison of pramipexole to ropinirole. Researchers 
found that both treatment groups improved RLS symptoms and reduced PLMs on PSG 
compared to the placebo group and that there was no significant differences between the 
pramipexole and ropinirole treatment arms (Manconi M et al. Mov Disorders 2011). In 
summary, pramipexole is a newer nonergot-derived dopamine agonist with preferential action 
on the D3 dopamine receptor site. It has been shown to be beneficial for both objective PSG 
PLM findings as well as subjective improvements in RLS clinical symptoms. It is generally 
well-tolerated although there may be an issue with augmentation long-term.  
Rotigotine is another newer nonergot-derived dopamine agonist. It is formulated as a once 
daily transdermal patch and approved to treat RLS in Europe but not FDA-approved for the 
USA. It appears to mainly work on the D2, D3, and D4 receptor sites. In one of the earliest 
pilot studies to show benefit for RLS patients, German researchers in 2004 evaluated 63 
patients. In this randomized, multicentre, double-blind, parallel-group trial, 63 subjects were 
studied using the IRLS severity score as the primary endpoint. Researchers found a significant 
improvement in the treatment group and concluded that transdermal rotigotine was 
efficacious and well-tolerated (Stiasny-Kolster K et al., 2004). More recently in a multicenter, 
randomized, double-blind, placebo-controlled 6 month trial, 505 patients with moderate to 
severe RLS were placed on placebo or rotigotine with the primary endpoints being the IRLS 
severity score and the CGI-1 score. The treatment group had significantly improved IRLS and 
CFI-1 outcomes. There was an overall 27% incidence of skin reactions to the transdermal 
patch. Overall, the authors concluded that rotigotine significantly reduced the severity of RLS 
symptoms and that treatment effectiveness was maintained throughout the 6 month study 
period (Hening WA et al., 2010). Rotigotine was also recently assessed in an overnight PSG 
study evaluating objective PLM measurements. This study was a multicenter, randomized, 
double-blind, placebo-controlled trial that evaluated 67 subjects over a 4 week period. Baseline 
and 4 week PSG and subjective questionnaires (IRLS, CGI-1, MOS-S) were obtained. The 
authors found significant improvements in both the subjective questionnaires but also the 
objective PSG PLM data. The researchers concluded that rotigotine was effective and well 
tolerated in the 4 week treatment of both motor symptoms and subjective sleep disturbances 
caused by RLS (Oertel WH et al., 2010). Finally, in a long term follow-up study, rotigotine was 
shown to provide sustained effectiveness in treating moderate to severe RLS symptoms for up 
to 5 years and was generally well-tolerated (Oertel W et al., 2011). 
7.1.5 Other pharmacological treatments for RLS 
A number of other therapies have be evaluated for RLS including opioids, gabapentin and 
pregabalin, clonazepam, and case reports of melatonin, buproprion, and other agents. 
Overall, there is a long experience with opioids and those drugs have been especially useful 
in dopaminergic resistant RLS with augmentation problems. Clonazepam has also been 
widely used but is not particularly efficacious and now has been largely replaced by 
dopaminergic agents. In April 2011, the FDA approved extended release gabapentin for use 
in moderate to severe RLS. This anticonvulsant agent has recently been shown to be 
beneficial in RLS and may be especially useful when dopamine agents provide incomplete 
resolution of RLS symptoms and/or augmentation issues arise. Please remember that the 
extended release form of gabapentin gives different concentrations of drug than the shorter 
acting form. Finally, it is important to note that all epilepsy drugs carry a suicide warning 
label including gabapentin. 
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7.2 Non-pharmacological treatments for RLS 
7.2.1 Exercise 
Traditionally, one of the basic clinical recommendations in treating RLS symptoms involves 
exercise and stretching maneuvers. This has been endorsed by the RLS Foundation 
(www.rls.org) in their latest patient brochure although the data supporting this is limited. 
There have been earlier studies by suggesting that exercise close to bedtime is 
counterproductive for RLS. In a large study, Ohayon assessed the prevalence of RLS and 
PLMD in the general population. During the multivariate analysis of the secondary results, the 
researchers (Ohayon, 2002) found that physical exercise close to bedtime (within 2 hours for at 
least 15 minutes exercise 3 or more times per week) was associated with an increased risk of 
RLS (OR 1.34, p<0.05) and PLMD (OR 1.43, p<0.05). However, in a conflicting study from 2000, 
Phillips et al. found that a lack of exercise was significantly associated with RLS. In a telephone 
survey of over 1800 participants, a single question (modified from the 1995 IRLSSG criteria) 
was used to screen for RLS. In this study, there was an age-adjusted prevalence of RLS of 
10.0% and a lack of exercise (less than 3 hours/month) was significantly associated with RLS 
(OR 3.32). In 1996, a Brazilian study evaluated 11 volunteers with to study the effect of acute 
physical activity on RLS and PLMD. In this report using a baseline PSG followed the next day 
by exercise and then a repeat PSG, there was a reduction in PLMD noted on the second night 
PSG (de Mello, 1996). In the only randomized-controlled trial of exercise in RLS, Aukerman 
studied 28 individuals in a 12 week exercise trial. The average age was 53.7 years and 39% of 
study subjects were male. Subjects were randomized to either a control group with usual 
activities or to an exercise group. The exercise program consisted of 3 days a week aerobic and 
lower extremity resistance/conditioning training. The IRLSSG severity scale and an RLS 
ordinal severity scale were checked at 0, 3, 6, 9, and 12 weeks. Of the 28 subjects, most (23) 
completed the trial with 11 in the exercise training group. The researchers found that the 
exercise group had a significant improvement in RLS symptoms compared to the control 
group with a p = 0.001 for the IRLSSG severity score and p < 0.001 for the RLS ordinal scale. 
The research team concluded that a prescribed exercise program is effective in improving RLS 
symptoms (Aukerman MM 2006). 
7.2.2 Sequential compression devices 
There is a hypothesis that reduced blood flow to the extremities may play a role in RLS 
symptoms. Research has been undertaken to ascertain whether sequential (pneumatic) 
compression devices may alleviate RLS symptomatology. In a small preliminary study from 
2005, researchers from New Jersey evaluated 6 patients using enhanced external counter 
pulsation (EECP) devices on the legs for one hour daily Monday to Friday for 7 weeks 
(Rajaram SS, 2004). All 6 patients met the 2003 IRLSSG criteria and were assessed with the 
IRLS rating scale (IRLSSS) before and after the intervention. It should be noted that 3 
subjects did not complete the IRLSSS until 4-5 months after EECP treatment. Further 
complicating the results, 4 of the 6 patients suffered from diabetic peripheral neuropathy 
and no electromyography or nerve conduction studies were done before or after EECP 
treatment to assess any potential neuropathy changes. Nevertheless, the research team 
found that the IRLS rating scale was significantly improved after EECP intervention and 
suggested that decreases in vascular flow may affect the nervous system (peripheral or 
central) causing the sensory symptoms of RLS. In a more rigorous prospective, randomized, 
double-blinded sham-controlled trial, Lettieri and Eliasson studied 35 subjects in 2009. 
Consecutive patients attending a sleep clinic for RLS for approached for recruitment. 41 RLS 
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patients were assessed for eligibility with 6 excluded (4 not meeting inclusion criteria and 2 
refused to participate). The remaining 35 patients were randomized into either therapeutic 
or sham treatment with a sequential compression device for 1 hour daily for 4 weeks. 
Validated questionnaires were administrated at the start and end of the intervention. These 
forms included the International Restless Legs Syndrome Study Group Severity Scale 
(IRLSSS), the Johns Hopkins Restless Legs Severity Scale (JHRLSS), and the restless legs 
syndrome quality of life instrument (RLS-QLI). Iron therapy and RLS pharmacological use 
was similar between the sham control and intervention groups. The researchers found 
significant improvements in the IRLSSS, JHRLSS, and the RLS-QLI for the intervention 
group and suggest that pneumatic compression devices are a useful adjunctive or 
alternative therapy for RLS (Lettieri CJ, 2009). 
7.2.3 Massage therapy 
Massage therapy has been long recommended as an additional therapy for RLS symptoms. 
However, there is a dearth of scientific evidence to support this claim. In a case report from 
2006, Russell presented a 35 year old women with RLS type symptoms. There was no 
indication whether the patient actually met the 2003 IRLSSG criteria. It was noted that the 
patient had previously tried ropinirole without benefit. In this case report, the patient was 
treated with twice weekly massage therapy of 45 minute duration to the lower extremities for 
a 3 week period and reported improvements on a subjective symptom intensity scale from 
40% at baseline to 10% at the end of therapy (Russell M, 2006). Interestingly, 2 weeks following 
the end of the massage intervention, the patient reported a return of her symptoms. Overall, 
there is a lack of scientific evidence to routinely support the use of massage therapy in RLS. 
7.2.4 Acupuncture 
Acupuncture has also been recommended by some as a therapy for RLS. Nonetheless, 
similar to massage therapy, there is minimal evidence to recommend acupuncture for RLS 
symptoms. In a Cochrane review, the authors found out of 14 potential studies only 2 met 
the inclusion criteria to be valid and both trials had methodological and/or reporting issues. 
Overall, the Cochrane reviewers felt that there was no significant data to support the use of 
acupuncture in RLS (Cui Y, 2008). 
7.2.5 Endovenous laser ablation & sclerotherapy 
Recently, Hayes and colleagues have reported on the use of endovenous laser ablation and 
sclerotherapy for the treatment of RLS. They screened 89 patients for RLS using the 2003 
IRLSSG criteria. A total of 35 patients met inclusion criteria with 16 assigned to the control 
group and 19 to the interventional group. IRLS scores were obtained at baseline and 6 weeks 
later and showed a significant symptom improvement of 80% in the interventional group. 
The authors suggest that endovenous laser ablation therapy improves symptoms in RLS 
patients with superficial venous insufficiency (Hayes CA, 2008). The only other study 
assessing the efficacy of sclerotherapy in RLS was published by Kanter in 1995. In that 
paper, 1397 patients presenting to a varicose vein clinic were screened for RLS using an 
interview and a questionnaire (pre-1995 IRLSSG). Of these, 312 patients (22%) were felt to 
have RLS with 113 patients receiving treatment with sclerotherapy. The vast majority of 
patients (98%) reported subjective initial improvement in RLS symptoms although a 
substantial minority reported recurrent symptoms at 2 year follow-up (Kanter AH, 1995). 
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8. Conclusion 
RLS is a common medical disorder which remains underdiagnosed. The underlying etiology 
is still not fully elucidated but there is increasing understanding of some mechanisms of 
disease especially in secondary RLS. Many treatment options are available although issues 
of augmentation and rebound continue to cause problems with RLS control. It is highly 
recommended that health care providers be aware of RLS symptoms and recognize the 
disease in their patients. 
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